Emerging biopharmaceutical company Actinova Ltd of the UK has nowlaunched a website at www.actinova.co.uk, which offers visitors an interactive resource on the company, its management team, products and technologies, up-to-date news on key developments and links to related sites. Actinova is engaged in the development of innovative new drugs and antibacterial vaccines, including a novel therapeutic for the prevention and treatment of tooth decay.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze